

SALIX PHARMACEUTICALS LTD

Form 8-K

November 25, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 24, 2014**

**SALIX PHARMACEUTICALS, LTD.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**000-23265**  
**(Commission**

**File Number)**

**94-3267443**  
**(I.R.S. Employer**

**Identification No.)**

**8510 Colonnade Center Drive**

**Raleigh, North Carolina**  
**(Address of principal executive offices)**

**27615**  
**(Zip Code)**

**Registrant's telephone number, including area code: (919) 862-1000**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On November 24, 2014, Salix Pharmaceuticals, Ltd. (the Company) issued a press release announcing that the Company has engaged Russell Reynolds Associates, a nationally recognized search firm, to conduct a comprehensive search to assist the Company in identifying experienced, highly qualified individuals to serve as independent members of the Company's Board of Directors.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit	Description
99.1	Press release issued by Salix Pharmaceuticals, Ltd. on November 24, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 24, 2014

SALIX PHARMACEUTICALS, LTD.

By: /s/ WILLIAM BERTRAND, JR.  
William Bertrand, Jr.  
Senior Vice President and General Counsel

**Exhibit Index**

Exhibit	Description
99.1	Press release issued by Salix Pharmaceuticals, Ltd. on November 24, 2014.